Bausch Health (BHC) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $1.24
- EPS estimate
- $0.98
- EPS surprise
- +26.71%
- Revenue surprise
- +8.74%
- Revenue
- $2.8B
- Revenue estimate
- $2.6B
- Reported
- Jul 29, 2026
Bausch Health reported Q2 2026 results on July 29, 2026. Earnings per share were $1.24, ahead of the $0.98 estimate by 26.71%. Revenue was $2.8 billion, 8.74% above the $2.6 billion consensus. Compared with Q2 2025, EPS rose about 17% from $1.06 and revenue rose from $2.6 billion.
Annual revenue grew from $8.2 billion in 2022 to $9.0 billion in 2023, $9.7 billion in 2024 and $10.3 billion in 2025. Annual EPS went from $3.14 in 2022 to $3.46 in 2023 and $4.03 in 2024, then eased to $3.87 in 2025. The first half of 2026 adds up to $2.00 per share, about 22% more than the first half of 2025. In 2023, 2024 and 2025, Q1 was the weakest quarter. Q2 2026 matched the table's revenue high of $2.8 billion, first reached in Q4 2025, and its EPS is second only to the $1.28 of Q4 2021. Bausch Health beat EPS estimates in 11 of the last 20 quarters.
Q3 results came between October 29 and November 3 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether the year-over-year gains continue.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | $0.98 | $1.24 | +26.71% | $2.8B | SEC |
| Q1 2026 | Apr 29, 2026 | $0.66 | $0.76 | +15.44% | $2.5B | SEC |
| Q4 2025 | Feb 18, 2026 | $1.21 | $1.07 | −11.55% | $2.8B | SEC |
| Q3 2025 | Oct 29, 2025 | $1.06 | $1.16 | +9.53% | $2.7B | SEC |
| Q2 2025 | Jul 30, 2025 | $0.93 | $1.06 | +13.76% | $2.6B | SEC |
| Q1 2025 | Apr 30, 2025 | $0.81 | $0.58 | −27.50% | $2.2B | SEC |
| Q4 2024 | Feb 19, 2025 | $1.13 | $1.13 | −0.05% | $2.5B | SEC |
| Q3 2024 | Oct 30, 2024 | $1.05 | $1.18 | +12.36% | $2.6B | SEC |
| Q2 2024 | Aug 1, 2024 | $0.88 | $1.08 | +22.59% | $2.4B | SEC |
| Q1 2024 | May 2, 2024 | $0.69 | $0.64 | −7.45% | $2.2B | SEC |
| Q4 2023 | Feb 22, 2024 | $1.04 | $0.99 | −4.74% | $2.5B | SEC |
| Q3 2023 | Nov 2, 2023 | $0.93 | $1.09 | +17.63% | $2.3B | SEC |
| Q2 2023 | Aug 3, 2023 | $0.71 | $0.83 | +16.63% | $2.2B | SEC |
| Q1 2023 | May 4, 2023 | $0.65 | $0.55 | −14.95% | $2.0B | SEC |
| Q4 2022 | Feb 23, 2023 | $0.94 | $1.05 | +10.91% | $2.2B | SEC |
| Q3 2022 | Nov 3, 2022 | $0.82 | $0.79 | −3.74% | $2.0B | SEC |
| Q2 2022 | Aug 9, 2022 | $0.91 | $0.55 | −39.14% | $2.0B | SEC |
| Q1 2022 | May 10, 2022 | $1.05 | $0.75 | −28.17% | $2.0B | SEC |
| Q4 2021 | Feb 23, 2022 | $1.11 | $1.28 | +15.42% | $2.2B | SEC |
| Q3 2021 | Nov 2, 2021 | $1.03 | $1.13 | +9.39% | $2.1B | SEC |
Quarterly revenue
Frequently asked questions
When did Bausch Health (BHC) last report earnings?
Bausch Health last reported on Jul 29, 2026, covering fiscal Q2 2026.
Did BHC beat earnings estimates?
Yes. Bausch Health reported EPS of $1.24 for Q2 2026 against a $0.98 estimate — a 26.71% beat.
How much revenue did BHC report last quarter?
Bausch Health reported $2.8B in revenue for Q2 2026, against a consensus estimate of $2.6B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.